Regarding kidney function, the DECREASE trial which enrolled 66 participants with obesity and type 2 diabetes showed a mean percentage change in 24-h urine albumin to creatinine ratio (UACR) of 40% with combination treatment including dapagliflozin and exenatide as opposed to 18% with dapagliflozin, 16% with exenatide and 11% with placebo [ 8 ], although between group differences did not reach statistical significance.
← all excerpts
SGLT-2 Inhibitors and GLP-1 Receptor Agonists as Combination Therapy in Type 2 Diabetes.
1
—
—